Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Progression free survival rate

<< Previous

Bullboard Posts

Next >>

Comment by Qwerty54321on Jun 01, 2024 10:55pm

86 Views

Post# 36067984

RE:Progression free survival rate

I get ur point but you have to look at what other lung cancer drugs are capable of doing. It's the limited affects of other drugs that make this one look good (in lung cancer).

scarlet1967 wrote:

This bispecific antibody stops immunosuppression and blood supply process both responsible for progression of the cancer. The drug is now approved in combo therapy for cancer in China!

Different MOA but one could not ignore long term efficacy of cancer drugs and their place in the market as a stand alone drug or in combination with chemotherapy.

I thought it was interesting to bring this up as sudocetaxel zendusortide managed to stabilize the disease for long time.

https://ca.finance.yahoo.com/news/summit-shares-soar-lung-cancer-195343904.html

https://ca.finance.yahoo.com/news/ivonescimab-combination-chemotherapy-approved-china-230000301.html